tbuckley/cabot-search huggingface dataset:
Effect of neoadjuvant chemotherapy regimen choice in patients with breast cancer with pathologic complete response.
Authors: Anna Weiss, Sami Bashour, Limin Hsu, Kenneth R. Hess, Alastair Mark Thompson, Nuhad K. Ibrahim
Journal: Journal of Clinical Oncology (2017)

570 Background: Breast cancer patients with a pathologic complete response (pCR) to neoadjuvant chemotherapy (NACT) have improved survival. We hypothesize there is no difference in post-surgical recurrence free survival (RFS) between regimens used if pCR has been achieved. Methods: Breast cancer patients treated with NACT (using various regimens) between 1996 and 2011 who achieved pCR were examined, using a prospectively maintained electronic database. RFS was estimated by Kaplan-Meier method, differences between groups assessed using log-rank test. Cox proportional hazards regression analysis adjusted for age, menopausal status, stage, grade, tumor subtype, and adjuvant treatments. Results: 721 patients were identified: 40.4% Stage IIA, 21.2% IIB, 10.8% IIIA, 9.2% IIIB, 18.3% IIIC. 21.8% were hormone receptor positive (HR), 43.3% HER2 amplified, 32.7% triple negative. 50.9% of patients were treated with adriamycin-based chemotherapy plus taxane (adriamycin+taxane), 7.8% without taxane (adriamycin-taxane), 31.5% HER2 targeted therapy, and 9.8% provider choice. Median follow up was 7.4 years. There was no significant difference in RFS by treatment group (table 1). Adjusted RFS hazard ratios comparing each treatment to adriamycin+taxane were 1.25 (95% confidence interval 0.47-3.35) adriamycin-taxane, 0.90 (CI 0.37-2.20) HER2 targeted, and 1.28 (CI 0.55-2.98) provider choice. Conclusions: These data suggest that post-surgical RFS among patients with pCR is not significantly influenced by the type of NACT. Meta-analysis of randomized trial data should be explored to evaluate these findings. If RFS of pCR patients is not affected by regimen, this could allow flexibility in treatment choice and length. [Table: see text]
The Increasing Call for Protective Ventilation During Anesthesia—Reply
Authors: Ana Fernandez-Bustamante, Marcos F. Vidal Melo
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Time-series Analysis of Heat Waves and Emergency Department Visits in Atlanta, 1993 to 2012
Authors: Tianqi Chen, Stefanie E. Sarnat, Andrew J. Grundstein, Andrea Winquist, Howard H. Chang
Journal: Environmental Health Perspectives (2017)

Background: Heat waves are extreme weather events that have been associated with adverse health outcomes. However, there is limited knowledge of heat waves’ impact on population morbidity, such as emergency department (ED) visits. Objectives: We investigated associations between heat waves and ED visits for 17 outcomes in Atlanta over a 20-year period, 1993–2012. Methods: Associations were estimated using Poisson log-linear models controlling for continuous air temperature, dew-point temperature, day of week, holidays, and time trends. We defined heat waves as periods of ≥2 consecutive days with temperatures beyond the 98th percentile of the temperature distribution over the period from 1945–2012. We considered six heat wave definitions using maximum, minimum, and average air temperatures and apparent temperatures. Associations by heat wave characteristics were examined. Results: Among all outcome-heat wave combinations, associations were strongest between ED visits for acute renal failure and heat waves defined by maximum apparent temperature at lag 0 [relative risk (RR) = 1.15; 95% confidence interval (CI): 1.03–1.29], ED visits for ischemic stroke and heat waves defined by minimum temperature at lag 0 (RR = 1.09; 95% CI: 1.02–1.17), and ED visits for intestinal infection and heat waves defined by average temperature at lag 1 (RR = 1.10; 95% CI: 1.00–1.21). ED visits for all internal causes were associated with heat waves defined by maximum temperature at lag 1 (RR = 1.02; 95% CI: 1.00, 1.04). Conclusions: Heat waves can confer additional risks of ED visits beyond those of daily air temperature, even in a region with high air-conditioning prevalence. https://doi.org/10.1289/EHP44
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
Authors: Eytan M. Stein, Courtney D. DiNardo, Daniel A. Pollyea, Amir T. Fathi, Gail J. Roboz, Jessica K. Altman, Richard M. Stone, Daniel J. DeAngelo, Ross L. Levine, Ian W. Flinn, Hagop M. Kantarjian, Robert Collins, Manish R. Patel, Arthur E. Frankel, Anthony Stein, Mikkael A. Sekeres, Ronan T. Swords, Bruno C. Medeiros, Christophe Willekens, Paresh Vyas, Alessandra Tosolini, Qiang Xu, Robert D. Knight, Katharine E. Yen, Sam Agresta, Stephane de Botton, Martin S. Tallman
Journal: Blood (2017)
Individual Confidence-Weighting and Group Decision-Making
Authors: James A.R. Marshall, Gavin Brown, Andrew N. Radford
Journal: Trends in Ecology & Evolution (2017)

Group-living species frequently pool individual information so as to reach consensus decisions such as when and where to move, or whether a predator is present. Such opinion-pooling has been demonstrated empirically, and theoretical models have been proposed to explain why group decisions are more reliable than individual decisions. Behavioural ecology theory frequently assumes that all individuals have equal decision-making abilities, but decision theory relaxes this assumption and has been tested in human groups. We summarise relevant theory and argue for its applicability to collective animal decisions. We consider selective pressure on confidence-weighting in groups of related and unrelated individuals. We also consider which species and behaviours may provide evidence of confidence-weighting, paying particular attention to the sophisticated vocal communication of cooperative breeders.
Rego-SARC: Activity and safety of regorafenib (RE) in patients with metastatic soft-tissue sarcoma (STS) previously treated with anthracyclin-based chemotherapy—A multinational, randomized, placebo-controlled phase II trial.
Authors: Stephanie Clisant, Nicolas Penel, Bernadette Lieg-Atzwanger, Viktor Gruenwald, Ferdinand Ploner, Sophie Taieb, Marie Vanseymortier, Axel Le Cesne, Wolfgang Eisterer, Olivier Mir, Antoine Italiano, Pierre Arvis, Andrew Kramar, Jean-Yves Blay, Thomas Brodowicz
Journal: Journal of Clinical Oncology (2014)

TPS10602 Background: Angiogenesis plays a key role in sarcoma biology. RE, targeting VEGFR-2 and -3, and tumor cell signaling kinases (RET, KIT, PDGFR, and Raf), has recently been shown to be effective in imatinib and sunitinib-refractory GIST in a phase III trial [Demetri, Lancet 2013]. Furthermore, the Palette trial has shown that pazopanib, another anti-angiogenic agent, significantly improved the PFS without OS advantage in anthracycline-refractory STS [Van Der Graaf, Lancet 2012]. Methods: We are conducting a multinational (France, Austria and Germany) double-blind placebo-controlled randomized (1/1) phase II trial to assess the activity and safety of RE in doxorubicin-refractory STS (ClinicalTrials.gov: NCT01900743). Key eligibility criteria are: measurable disease, age ≥18, less than 4 previous lines of CT, metastatic disease not amenable to surgical resection. Applied stratification criteria are: histological types (liposarcoma, leiomyosarcoma, synovial s., and others), countries and previous use of pazopanib. The primary endpoint is PFS according to central radiological review. Each stratum defined by histology will be separately analyzed. Statistical assumptions are: PFS0=1.6 and PFS1=4.6 months; 1-sided α=0.1; β=0.05 with a total sample size of 192 pts. Tumor assessment is done monthly during the 4 first months, and every 3 months thereafter. After central radiological confirmation of tumor progression, an optional cross-over is proposed. Secondary endpoints are: toxicity (NCI-CTC AE V4.0); TTP; growth modulation index in pts receiving RE after randomization (GMI=TTP with RE/TTP with the prior treatment), 3 and 6 months PFS-Rates, best RR, OS. The exploratory translational research program will further characterize the nature of the genetic change by exploring the mutational status of the tumor samples using the Ion AmpliSeq Cancer Panel. In addition tissue-micro arrays (TMA) from FFPE material will be generated to allow a large-scale evaluation of molecular aberrations and downstream effects on pathway activation. The study is enrolling since June 2013. Clinical trial information: ClinicalTrials.gov: NCT01900743.
Commentaire de travail de S. von Delius et al., pp. 407
Authors: A N et al Kallo
Journal: Endoscopy (2007)

See also: Transgastric in vivo histology in the peritoneal cavity using miniprobe-based confocal fluorescence microscopy in an acute porcine modelEndoscopy 2007; 39(05): 407-411DOI: 10.1055/s-2007-966439
Attacks against health care in Syria, 2015–16: results from a real-time reporting tool
Authors: Mohamed Elamein, Hilary Bower, Camilo Valderrama, Daher Zedan, Hazem Rihawi, Khaled Almilaji, Mohammed Abdelhafeez, Nabil Tabbal, Naser Almhawish, Sophie Maes, Alaa AbouZeid
Journal: The Lancet (2017)
Abstract P344: A Natural p300-Specific Histone Acetyltransferase Inhibitor, Curcumin, Prevents the Development of Heart Failure in Addition to ACE Inhibitor After Myocardial Infarction in Rats
Authors: Tatsuya Morimoto, Yoichi Sunagawa, Hiromichi Wada, Yasufumi Katanasaka, Tomohide Takaya, Teruhisa Kawamura, Shigeki Yanagi, Akira Marui, Ryuzo Sakata, Akira Shimatsu, Takeshi Kimura, Masatoshi Fujita, Koji Hasegawa
Journal: Circulation Research (2011)

Background: We found that curcumin, a p300 histone acetyltransferase (HAT) inhibitor, prevents deterioration of the systolic function in rat heart failure models in vivo. To clinically apply this novel therapy to humans, it should be clarified whether or not curcumin has additional effects on conventional heart failure therapy comprising angiotensin-converting enzyme inhibitors (ACEI). Methods and Results: Rats were subjected to a sham operation or myocardial infarction (MI). One week later, 32 rats were randomly assigned to solvents (control), enalapril (ACEI, 10 mg/kg/day) alone, curcumin (50 mg/kg/day) alone, or curcumin plus enalapril for 6 weeks. ACEI, but not curcumin treatment, decreased the blood pressure in post-MI rats. After treatment, LVFS (fractional shortening) was significantly ( p &lt;0.05) higher in the ACEI (29%) and curcumin (29%) groups than in the vehicle group (22%). Notably, LVFS significantly ( p &lt;0.05) increased on ACEI/ curcumin combination therapy (35%) compared with therapy comprising either ACEI or curcumin alone. The LV wall thickness and cardiomyocyte diameter were significantly smaller in the ACEI/curcumin than the ACEI group. Moreover, perivascular fibrosis was significantly reduced in the ACEI and curcumin groups compared with the vehicle group. This reduction was further augmented by the ACEI/ curcumin combination therapy. Conclusion: Curcumin, restores the post-MI LV systolic function in rats without affecting the blood pressure. This natural non-toxic dietary compound in addition to ACEI has beneficial effects on LV systolic function.
Adjuvant treatment decision in patients with node-negative, ER+/Her2-, early stage breast cancer with Oncotype DX (ODX) recurrence score (RS) of 11-30: Impact of clinicopathologic features.
Authors: Gwenalyn Garcia, Shiksha Kedia, Nishitha Thumallapally, Elias Moussaly, Saqib Abbasi, Srujitha Murukutla, Qun Dai
Journal: Journal of Clinical Oncology (2017)

e12022 Background: The ODX RS predicts the risk of distant recurrence and the benefit of adjuvant chemotherapy (CT) in patients with ER+/Her2- breast cancer. High RS predicts a large benefit whereas low RS predicts minimal benefit from CT. A prospective trial showed that patients with low RS of 0-10 may be safely spared adjuvant CT. Recommendations in patients with intermediate RS are less clear. We performed a retrospective study of adjuvant therapy decision in patients with RS 11-30. Methods: We identified patients with ER+/Her2-, node-negative breast cancer with ODX RS 11-30 treated at our center from 2010-2016. Data on patient age, type of surgery, tumor size, grade, lymphovascular invasion (LVI), RS and treatment were collected. Statistical associations were tested using Chi square/Fisher's exact test and t test. Logistic regression analysis was used to determine odds ratios (OR). Results: 76 patients were identified. 86% (65/76) of them received adjuvant endocrine therapy alone and 14% (11/76) received adjuvant CT plus endocrine therapy. Patient characteristics are shown in the table. Using univariate analysis, significant predictors of receiving CT included RS, LVI, and ER positivity. In the patients who received CT, RSs were all ≥ 18 whereas in the group who did not receive CT, 42% (27/65) patients had RS 11-17. Increase in RS was associated with increase in the likelihood of receiving CT (OR 1.40, 95% CI 1.14-1.74, p=0.00017). Decrease in ER positivity was correlated with increased likelihood of receiving CT (OR 0.922, 95% CI 0.856-0.992, p=0.03). The presence of LVI increased the likelihood of receiving CT (OR 26.24, 95% CI 4.16-165.43, p=0.0005). Conclusions: In patients with ER+/Her2-, node-negative breast cancer with RS 11-30, the majority received endocrine therapy alone. RS and some clinicopathologic features (LVI, ER) impacted the decision to receive CT. [Table: see text]
Modulation of <i>Salmonella</i> Tumor-Colonization and Intratumoral Anti-angiogenesis by Triptolide and Its Mechanism
Authors: Jianxiang Chen, Yiting Qiao, Bo Tang, Guo Chen, Xiufeng Liu, Bingya Yang, Jing Wei, Xiangyu Zhang, Xiawei Cheng, Pan Du, Wenhui Jiang, Qingang Hu, Zi-Chun Hua
Journal: Theranostics (2017)

The weakened tumour colonization of attenuated Salmonella has severely hampered its clinical development.In this study, we investigated whether an anti-inflammation and antiangiogenesis compound triptolide could improve the efficacy of VNP20009, a highly attenuated Salmonella strain, against mice melanoma.By comparing the effects of conventional VNP20009 monotherapy and a combination therapy that uses both triptolide and VNP20009, we found that triptolide significantly improved the tumour colonization of VNP20009 by reducing the number of infiltrated neutrophils in the melanoma, which led to a larger necrotic area in the melanoma.Moreover, the combination therapy suppressed tumour angiogenesis by reducing the expression of VEGF in a synergistic manner, retarding the growth of the melanoma.Our study revealed that triptolide could significantly enhance the antitumour effect of VNP20009 by modulating tumour angiogenesis and the host immune response, providing a new understanding of the strategy to improve Salmonella-mediated tumour therapy.
Abstract P293: Endogenous Lats2 Plays an Important Role in Mediating Myocardial Injury Caused by Ischemia/Reperfusion Through Inhibition of FoxO3
Authors: Dan Shao, Peiyong Zhai, Junichi Sadoshima
Journal: Circulation Research (2011)

Lats2 is a tumor suppressor and a serine/threonine kinase, acting downstream of mammalian sterile 20 like kinase1 (Mst1), which stimulates apoptosis and inhibits hypertrophy in cardiomyocytes (CM). We investigated the role of Lats2 in mediating myocardial injury after ischemia/reperfusion (IR). Phosphorylation of YAP, an in vivo substrate of Lats2, was increased after 45 minutes ischemia followed by 24 hours reperfusion in control mouse hearts compared with sham, but not in dominant negative (DN) Lats2 transgenic mouse (Tg) hearts, suggesting that Lats2 is activated by IR. The size of myocardial infarction (MI)/area at risk was significantly smaller in Tg mice than in NTg mice (19% and 49%, p&lt;0.01). And there were fewer TUNEL positive cells in Tg than in NTg mice (0.04% and 0.11%, p&lt;0.05). Following 30 min of global ischemia and 60 min of reperfusion in Langendorff perfused heart preparations, left ventricular (LV) systolic pressure (100 vs 71mmHg, p&lt;0.05) and LV developed pressure (79 vs 47 mmHg, p&lt;0.05) were significantly greater in Tg than in NTg mice, indicating that suppression of Lats2 induces better functional recovery after IR. Oxidative stress, as evaluated by 8-OHdG staining, was attenuated in Tg mice. In cultured CMs, DN-Lats2 significantly decreased H 2 O 2 -induced cell death. Overexpression of Lats2 significantly downregulated (51% and 75%, p&lt;0.05), whereas that of DN-Last2 upregulated (100 and 70%, p&lt;0.05), MnSOD and catalase, suggesting that Lats2 negatively regulates expression of antioxidants. Reporter gene assays showed that overexpression of Lats2 significantly inhibits (−70%), whereas knocking down Lats2 by sh-Lats2 increases (+60%), FoxO3-mediated transcriptional activity. Overexpression of Lats2 in CMs inhibited FoxO3 expression, whereas that of DN-Lats2 significantly inhibited FoxO3 downregulation after IR in vivo, suggesting that Lats2 negatively regulates FoxO3 protein expression, which may lead to the downregulation of MnSOD and catalase. Taken together, these results suggest that endogenous Lats2 plays an important role in mediating myocardial injury in response to IR, In part through downregulation of FoxO3 and consequent downregulation of antioxidants and increased oxidative stress in the heart.
In Reply
Authors: Jennifer J. Griggs, Eva Culakova, Melony E.S. Sorbero, Gary H. Lyman
Journal: Journal of Clinical Oncology (2007)

more frequent adverse effects in a community-based population compared with patients in clinical trials.They note that some of the differences may be due to the gradient of socioeconomic status and health.Gross et al 3 confirm that participation in clinical trials is a surrogate for higher socioeconomic status in breast cancer patients.Like most other cooperative studies, the classic Bonnadonna and Valagussa trial 4 documenting a dose/primary end point relationship was not stratified by socioeconomic status.I suspect at least some of their differences in dose-intensity may correlate with toxicity.In other words, excess toxicity may negate the benefits of high-quality chemotherapy in patients of lower socioeconomic status.It seems logical that oncologists would prescribe lower first chemotherapy doses based on a realistic concern over higher toxicity in this population.Further prospective studies will solve these and other socioeconomic conundrums.The gradient of socioeconomic status and health is based on complex interactions between health care, environment, and patient behavioral patterns. 5Griggs' study 1 should stimulate further research in this rapidly evolving discipline.
Impact of Treatment Center Characteristics on Early Death Rates in Patients with Newly Diagnosed Acute Promyelocytic Leukemia: Analysis of Data from the SEER Program
Authors: Jae H. Park, Sean Devlin, Charles Lynch, Ann Schwartz, Theresa Keegan, Lou Gonsalves, Kim Hermit, Michael Green, Dan Douer, Martin S. Tallman
Journal: Blood (2016)
Outcome of palbociclib based therapy in hormone receptor positive metastatic breast cancer patients after treatment with everolimus.
Authors: Ajay Dhakal, Christina Matthews, Fan Zhang, Ellis Glenn Levine, Stephen B. Edge, Kilian Elizabeth Salerno, Tracy O'Connor, Amy P. Early, Thaer Khoury, Kazuaki Takabe, Jessica S. Young, Mateusz Opyrchal
Journal: Journal of Clinical Oncology (2017)

1054 Background: Resistance mechanisms to CDK 4/6 inhibition are not well defined. Outcome data on hormone receptor positive (HR+) metastatic breast cancer patients (MBCP) treated with palbociclib (PA) after treatment with everolimus (EV) are lacking. The PALOMA 3 trial (P3) showing benefit of PA plus fulvestrant (FU) compared to FU in HR+ MBCP after progression on endocrine therapy excluded women previously treated with EV. The aim of our study was to investigate the outcomes of HR+ MBCP with prior EV treatment on PA based therapy. Methods: This is a retrospective, single institute review of HR+, HER 2 nonamplified MBCP from Jan 2014 - Nov 2016 treated with PA after treatment with EV. Women who received EV for &lt; 1 month or PA &lt; 14 days were excluded. Progression free survival (PFS) was defined as the time from the initiation of PA to the date of progression as determined by treating physician based on radiological, biochemical and/or clinical criteria. Response rates were determined based on available radiological data. Clinical benefit was defined as a complete response (CR), partial response (PR) or stable disease of at least 24 weeks. Results: 23 patients with mean age 67 years (42 to 81) were identified. 95% were postmenopausal, 81% had ECOG performance status 0 or 1, 83% had visceral metastases, 95% had &gt; 2 lines of prior endocrine therapy (ET), 82% shown prior sensitivity to ET, 82% received prior chemotherapy, of which 84% were in metastatic setting. Kaplan Meier estimate showed median PFS of 2.9 months (95% CI 2.0-4.2); median PFS of P3 PA cohort was 9.5 months (95% CI 9.2-11.0). Fisher’s exact test comparing study cohort with P3 PA cohort showed statistically significant differences in objective response (CR or PR) rates of 0/23 (0%) vs. 66/347 (19%, p = 0.02) &amp; clinical benefit ratio of 4/23 (17.4%) vs. 231/347 (66.5%, p = 0.00). Conclusions: Outcomes with PA in HR+ EV treated MBCP were worse when compared to the P3 PA cohort data. Treatment with EV may lead to resistance to CDK inhibition. Though limited by size, our data suggests that use of PA after EV is associated with low response &amp; clinical benefit rates. Further studies are necessary to confirm the findings to determine sequencing of targeted therapies.
Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma
Authors: Tyler J. Moss, Yuan Qi, Liu Xi, Bo Peng, Tae-Beom Kim, Nader E. Ezzedine, Maribel E. Mosqueda, Charles C. Guo, Bogdan A. Czerniak, Michael Ittmann, David A. Wheeler, Seth P. Lerner, Surena F. Matin
Journal: European Urology (2017)